Business Description
TME Pharma NV
ISIN : NL0015000YE1
Total Employee Number:
13Compare
Compare
Traded in other countries / regions
ALTME.France0N6A.Germany IPO Date
2018-09-10Description
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.84 | |||||
Equity-to-Asset | -0.74 | |||||
Debt-to-Equity | -1.51 | |||||
Debt-to-EBITDA | -1.09 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 85.4 | |||||
3-Year EPS without NRI Growth Rate | 85.4 | |||||
3-Year FCF Growth Rate | 83.3 | |||||
3-Year Book Growth Rate | 67.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.88 | |||||
9-Day RSI | 35.49 | |||||
14-Day RSI | 36.02 | |||||
3-1 Month Momentum % | -10.81 | |||||
6-1 Month Momentum % | 2.62 | |||||
12-1 Month Momentum % | -37.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.57 | |||||
Quick Ratio | 0.57 | |||||
Cash Ratio | 0.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -232.9 | |||||
Shareholder Yield % | -35.34 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -18771.43 | |||||
ROA % | -125.73 | |||||
ROIC % | -153.51 | |||||
3-Year ROIIC % | -446.21 | |||||
ROC (Joel Greenblatt) % | -12669.23 | |||||
ROCE % | -12548.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.87 | |||||
EV-to-EBITDA | -2.88 | |||||
EV-to-Forward-Revenue | 0.42 | |||||
EV-to-FCF | -1.81 | |||||
Earnings Yield (Greenblatt) % | -34.82 | |||||
FCF Yield % | -57.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TME Pharma NV Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.03 | ||
| Beta | 1.1791 | ||
| 3-Year Sharpe Ratio | -0.67 | ||
| 3-Year Sortino Ratio | -0.81 | ||
| Volatility % | 70.76 | ||
| 14-Day RSI | 36.02 | ||
| 14-Day ATR (€) | 0.008499 | ||
| 20-Day SMA (€) | 0.062705 | ||
| 12-1 Month Momentum % | -37.8 | ||
| 52-Week Range (€) | 0.0333 - 0.1306 | ||
| Shares Outstanding (Mil) | 94.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TME Pharma NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TME Pharma NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.01:1 Stock Split | 2022-07-28 | 2.56 (+0.00%) |
Show
Entries
TME Pharma NV Frequently Asked Questions
What is TME Pharma NV(FRA:0N6A)'s stock price today?
The current price of FRA:0N6A is €0.06. The 52 week high of FRA:0N6A is €0.13 and 52 week low is €0.03.
When is next earnings date of TME Pharma NV(FRA:0N6A)?
The next earnings date of TME Pharma NV(FRA:0N6A) is .
Does TME Pharma NV(FRA:0N6A) pay dividends? If so, how much?
TME Pharma NV(FRA:0N6A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on TME Pharma NV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers